Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators hypothesize that the addition of antioxidant BMX-010 to
perfusion solution, digestion solution and culture medium during islet isolation process, can
lead to greater preservation of islet mass and metabolic function, such as improved islet
yield, viability, and functional potency.
This pilot study will involve up to 10 participants from the islet transplant waiting list at
the Clinical Islet Transplant Program. All participants will receive islets isolated with the
medication BMX-010. This is to assess the primary safety of BMX-010 on pancreata and islets.
BMX-010 will be used only in the islet isolation process, and will not be given to
participants as medication.